12 results on '"Han, Cheng-Long"'
Search Results
2. A model based on adipose and muscle-related indicators evaluated by CT images for predicting microvascular invasion in HCC patients
- Author
-
Mao, Xin-Cheng, Shi, Shuo, Yan, Lun-Jie, Wang, Han-Chao, Ding, Zi-Niu, Liu, Hui, Pan, Guo-Qiang, Zhang, Xiao, Han, Cheng-Long, Tian, Bao-Wen, Wang, Dong-Xu, Tan, Si-Yu, Dong, Zhao-Ru, Yan, Yu-Chuan, and Li, Tao
- Published
- 2023
- Full Text
- View/download PDF
3. Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades
- Author
-
Han, Cheng-Long, Yan, Yu-Chuan, Yan, Lun-Jie, Meng, Guang-Xiao, Yang, Chun-Cheng, Liu, Hui, Ding, Zi-Niu, Dong, Zhao-Ru, Hong, Jian-Guo, Chen, Zhi-Qiang, and Li, Tao
- Published
- 2023
- Full Text
- View/download PDF
4. Role of hepatitis B core‐related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta‐analysis.
- Author
-
Cao, Qi‐Hang, Liu, Hui, Yan, Lun‐Jie, Wang, Han‐Chao, Ding, Zi‐Niu, Mao, Xin‐Cheng, Li, Rui‐Zhe, Pan, Guo‐Qiang, Zhang, Xiao, Tian, Bao‐Wen, Han, Cheng‐Long, Dong, Zhao‐Ru, Tan, Si‐Yu, Wang, Dong‐Xu, Yan, Yu‐Chuan, and Li, Tao
- Subjects
HEPATITIS associated antigen ,CHRONIC hepatitis B ,HEPATOCELLULAR carcinoma ,SCIENCE databases ,ODDS ratio - Abstract
Background and Aim: The purpose of the current study was to investigate the predictive value of hepatitis B core‐related antigen (HBcrAg) on the occurrence and recurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). Methods: We searched PubMed, Embase, Scopus, and Web of Science from database inception to April 6, 2023. Pooled hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) was calculated for the occurrence and recurrence of HCC. Results: Of the 464 articles considered, 18 articles recruiting 10 320 patients were included. The pooled results showed that high serum HBcrAg level was an independent risk factor for the occurrence of HCC in CHB patients (adjusted HR = 3.12, 95% CI: 2.40–4.06, P < 0.001, I2 = 43.2%, P = 0.043; OR = 5.65, 95% CI: 3.44–5.82, P < 0.001, I2 = 0.00%, P = 0.42). Further subgroup analysis demonstrated that the predictive ability of HBcrAg for the occurrence of HCC is not influenced by the hepatitis B e antigen (HBeAg) status or the use of nucleoside/nucleotide analogs (NAs). In addition, our meta‐analysis also suggests that HBcrAg is a predictor of HCC recurrence (adjusted HR = 1.71, 95% CI: 1.26–2.32, P < 0.001, I2 = 7.89%, P = 0.031). Conclusions: For patients with CHB, serum HBcrAg may be a potential predictive factor for the occurrence of HCC, regardless of HBeAg status or NA treatment. It may also serve as a novel prognostic biomarker for the recurrence of HCC. More studies are needed to confirm our conclusions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
- Author
-
Han, Cheng-Long, Tian, Bao-Wen, Yan, Lun-Jie, Ding, Zi-Niu, Liu, Hui, Pan, Guo-Qiang, Zhang, Xiao, Mao, Xin-Chen, Tan, Si-Yu, Li, Rui-Zhe, Wang, Dong-Xu, Dong, Zhao-Ru, Yan, Yu-Chuan, and Li, Tao
- Subjects
IMMUNE checkpoint inhibitors ,HEPATOCELLULAR carcinoma ,IPILIMUMAB ,ONCOLOGY - Abstract
The effect of age, sex, and eastern cooperative oncology group performance status (ECOG PS) on the efficacy and safety of immune checkpoint inhibitor (ICI) therapy among hepatocellular carcinoma (HCC) patients remains elusive. Thus, a meta-analysis was conducted to evaluate whether such effects exist. Eligible studies in PubMed, Embase, and Cochrane Library databases were retrieved. One-hundred-and-eleven studies involving 14,768 HCC patients were included. The findings indicated that the ECOG PS didn't have a significant effect on the ORR and PFS in ICI-treated HCC patients (higher ECOG PS vs. lower ECOG PS: ORR: OR = 0.78, 95%CI = 0.55–1.10; PFS: HR = 1.15, 95%CI = 0.97–1.35), while those patients with a higher ECOG PS may have a worse OS (HR = 1.52, 95% CI = 1.26–1.84). There is no significant evidence of the effect of age (older vs. younger) or sex (males vs. females) on the efficacy of ICI therapy in HCC. ICI therapy in HCC should not be restricted strictly to certain patients in age or sex categories, while HCC patients with higher ECOG PS may require closer medication or follow-up strategy during ICI therapy. CRD42024518407 [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis.
- Author
-
Li, Han, Liu, Hui, Yan, Lun-Jie, Ding, Zi-Niu, Zhang, Xiao, Pan, Guo-Qiang, Han, Cheng-Long, Tian, Bao-Wen, Tan, Si-Yu, Dong, Zhao-Ru, Wang, Dong-Xu, Yan, Yu-Chuan, and Li, Tao
- Subjects
NON-alcoholic fatty liver disease ,HEPATOCELLULAR carcinoma ,BIOMARKERS - Abstract
The incidence of nonalcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) is increasing globally. We aimed to assess the performance of alpha-fetoprotein (AFP), AFP-L3, des-gamma-carboxy prothrombin (DCP), and GALAD score in detecting NAFLD-related HCC. We searched the relevant literature in PubMed, Embase and Cochrane. Conventional and network meta-analyses were performed for sensitivity, specificity, Youden index (YI), and the area under the summary receiver operator characteristic curve (AUC). Fifteen studies involving 2031 NAFLD participants were included in this meta-analysis. When detecting early-stage NAFLD-related HCC, GALAD score and DCP process excellent performance. The sensitivity and AUC of DCP (0.60, 0.74, respectively) were higher than AFP (0.34, 0.59, respectively). The network meta-analysis showed that DCP and GALAD score had similar performance. In detecting all-stage NAFLD-related HCC, GALAD score (sensitivity = 0.87; YI = 0.77) performed better than AFP (sensitivity = 0.56; YI = 0.50), AFP-L3 (sensitivity = 0.39; YI = 0.36) and DCP (sensitivity = 0.73; YI = 0.62). Network meta-analysis obtained consistent results with conventional meta-analysis. Due to the lower cost-effectiveness, DCP was more suitable for detecting early NAFLD-related HCC. AFP could be used in detecting all-stage NAFLD-related HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.
- Author
-
Han, Cheng-Long, Tian, Bao-Wen, Yan, Lun-Jie, Ding, Zi-Niu, Liu, Hui, Mao, Xin-Cheng, Tian, Jin-Cheng, Xue, Jun-Shuai, Tan, Si-Yu, Dong, Zhao-Ru, Yan, Yu-Chuan, Hong, Jian-Guo, Chen, Zhi-Qiang, Wang, Dong-Xu, and Li, Tao
- Subjects
- *
IMMUNE checkpoint inhibitors , *HEPATOCELLULAR carcinoma , *DRUG side effects , *IPILIMUMAB , *PROGRESSION-free survival , *MULTIVARIATE analysis - Abstract
Background and aims: The impacts of macrovascular invasion (MVI) or extrahepatic spread (EHS) on the efficacy and safety of immune checkpoint inhibitors (ICIs) among hepatocellular carcinoma (HCC) patients remain unclear. Thus, we conducted a systematic review and meta-analysis to clarify whether ICI therapy is a feasible treatment option for HCC with MVI or EHS. Methods: Eligible studies published before September 14, 2022, were retrieved. In this meta-analysis, the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and occurrence of adverse events (AEs) were outcomes of interest. Results: Fifty-four studies involving 6187 individuals were included. The findings indicated that the presence of EHS in ICI-treated HCC patients may indicate an inferior ORR (OR 0.77, 95% CI 0.63–0.96), but may not significantly affect the PFS (multivariate analyses: HR 1.27, 95% CI 0.70–2.31) and OS (multivariate analyses: HR 1.23, 95% CI 0.70–2.16). Additionally, the presence of MVI in ICI-treated HCC patients may not have significant prognostic impact on ORR (OR 0.84, 95% CI 0.64–1.10), but may indicate inferior PFS (multivariate analyses: HR 1.75, 95% CI 1.07–2.84) and OS (multivariate analyses: HR 2.03, 95% CI 1.31–3.14). The presence of EHS or MVI in ICI-treated HCC patients may not significantly impact the occurrence of any serious immune-related adverse events (irAEs) (grades ≥ 3) (EHS: OR 0.44, 95% CI 0.12–1.56; MVI: OR 0.68, 95% CI 0.24–1.88). Conclusion: The presence of MVI or EHS in ICI-treated HCC patients may not significantly impact the occurrence of serious irAEs. However, the presence of MVI (but not EHS) in ICI-treated HCC patients may be a significant negative prognostic factor. Therefore, ICI-treated HCC patients with MVI warrant more attention. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis.
- Author
-
Liu, Hui, Han, Cheng-Long, Tian, Bao-Wen, Ding, Zi-Niu, Yang, Ya-Fei, Ma, Yun-Long, Yang, Chun-Cheng, Meng, Guang-Xiao, Xue, Jun-Shuai, Wang, Dong-Xu, Dong, Zhao-Ru, Chen, Zhi-Qiang, Hong, Jian-Guo, and Li, Tao
- Subjects
HEPATITIS B ,CHRONIC hepatitis B ,HEPATOCELLULAR carcinoma ,CANCER prognosis ,HEPATITIS B virus ,TENOFOVIR - Abstract
Tenofovir (TDF) and entecavir (ETV) are first-line treatments for patients with chronic hepatitis B virus (HBV) infection. However, the effect of TDF versus ETV on the prognosis of HBV-related hepatocellular carcinoma (HCC) has not been fully clarified yet. PubMed, Embase and Web of science were searched up to March, 2021. Meta-analyses were performed for overall survival (OS), disease-free survival (DFS) and recurrence-free survival (RFS) to assess the effect of TDF versus ETV on the prognosis of HBV-related HCC. A total of 10 studies comprising 4706 Asian patients were included. The pooled results revealed that TDF was associated with better OS (adjusted HR = 0.50, 95% CI: 0.40–0.62; I
2 = 36.0%, p = 0.167) and better RFS/DFS (adjusted HR = 0.70, 95% CI: 0.55–0.89, I2 = 71.9%, p = 0.002) than ETV in treatment of HBV-related HCC. Subgroup analysis revealed that OS benefit from TDF was generally consistent, except for patients who underwent non-surgical treatment for HCC. Subgroup analysis also indicated that TDF reduces the risk of late recurrence (HR = 0.41, 95% CI: 0.18–0.0.93; I2 = 63.0%, p = 0.067) rather than early recurrence (HR = 0.99, 95% CI: 0.64–1.52; I2 = 61.3%, p = 0.076). Compared with ETV, TDF has the advantage of improving OS and reducing late recurrence of patients with HBV-related HCC patients who underwent resection. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
9. The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: a systematic review and meta-analysis.
- Author
-
Han, Cheng-Long, Tian, Bao-Wen, Yang, Chun-Cheng, Yang, Ya-Fei, Ma, Yun-Long, Ding, Zi-Niu, Yan, Lun-Jie, Liu, Hui, Dong, Zhao-Ru, Chen, Zhi-Qiang, Hong, Jian-Guo, Wang, Dong-Xu, and Li, Tao
- Subjects
HEPATOCELLULAR carcinoma ,HEPATITIS B virus ,UNIVARIATE analysis ,MULTIVARIATE analysis ,HEPATITIS C ,FATTY liver - Abstract
Fatty liver (FL) is reportedly a risk factor for hepatocellular carcinoma (HCC) in individuals affected with Hepatitis C (HCV) or B (HBV) virus. However, the results are contradictory, necessitating a meta-analysis. Sixteen relevant studies involving 88,618 individuals were retrieved from the Cochrane Library, PubMed, MEDLINE, Embase, and Scopus databases from their inception to 10 December 2022. The hazard ratios (HR) and 95% confidence intervals (CI) were analyzed. Liver biopsy-proven FL may be a significant risk factor for HCC in individuals affected with HBV (univariate analyses: HR = 3.13, 95% CI = 1.69–5.79; multivariate analyses: HR = 3.42, 95% CI = 0.83–14.09) as well as HCV (univariate analyses: HR = 1.64, 95% CI = 0.93–2.90; multivariate analyses: HR = 1.75, 95% CI = 1.02–3.00). However, the presence of FL confirmed using reasonable methods other than liver biopsy may not indicate a risk for HCC in HBV-infected individuals (univariate analyses: HR = 0.90, 95% CI = 0.44–1.81; multivariate analyses: HR = 0.69, 95% CI = 0.45–1.08). Biopsy-proven FL may be a significant risk factor for HCC in HCV/HBV-infected individuals. Thus, such individuals should receive suitable interventions to prevent HCC formation or at least attenuate the risk of HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.
- Author
-
Tian, Bao-Wen, Yan, Lun-Jie, Ding, Zi-Niu, Liu, Hui, Meng, Guang-Xiao, Xue, Jun-Shuai, Han, Cheng-Long, Dong, Zhao-Ru, Hong, Jian-Guo, Chen, Zhi-Qiang, Wang, Dong-Xu, and Li, Tao
- Subjects
ALPHA fetoproteins ,IMMUNE checkpoint inhibitors ,HEPATOCELLULAR carcinoma ,SURVIVAL rate ,OVERALL survival ,PROGNOSIS - Abstract
The prognostic value of alpha-fetoprotein (AFP) response for efficacy of targeted therapy or immune checkpoint inhibitors (ICIs) has not been established. The purpose of this meta-analysis is to elucidate the relationship between AFP response and survival outcomes in hepatocellular carcinoma (HCC) patients who received targeted therapy or ICIs. The hazard ratio (HR) with 95% confidence interval (CI) was used to evaluate the relationship between AFP response and overall survival (OS)/progression-free survival (PFS). Twenty-six articles containing 3056 HCC patients were finally included in the study. The pooled results showed that after targeted therapy or ICIs, patients with decrease in AFP had better prognosis (OS:HR = 0.48, 95%CI:0.40–0.56; PFS:HR = 0.39, 95%CI:0.33–0.46), while patients with increase in AFP had worse prognosis (OS:HR = 2.30, 95%CI:1.82–2.89; PFS:HR = 2.34, 95%CI = 1.69–3.24). Subgroup analysis revealed that compared to AFP decrease >50%, AFP decrease >20% can better predict the prognosis of patients who received targeted therapy (OS:HR = 0.51, 95%CI:0.41–0.62; PFS:HR = 0.39, 95%CI:0.30–0.51) or ICIs treatment (OS:HR = 0.34, 95%CI:0.16–0.71; PFS:HR = 0.22, 95%CI:0.10–0.47), and 8 weeks after targeted therapy may be the appropriate time point for AFP assessment. AFP decrease >20% within 8 weeks may be the appropriate definition for early AFP response which probably works best in predicting the efficacy of therapy. The review was not registered. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma.
- Author
-
Tian, Bao-Wen, Han, Cheng-Long, Dong, Zhao-Ru, Tan, Si-Yu, Wang, Dong-Xu, and Li, Tao
- Subjects
- *
EXOSOMES , *IMMUNE checkpoint inhibitors , *CELLULAR therapy , *CELL physiology , *TREATMENT effectiveness , *CELL lines , *IMMUNOTHERAPY , *HEPATOCELLULAR carcinoma - Abstract
Simple Summary: Hepatocellular carcinoma is one of the most lethal malignancies, having a significantly poor prognosis. Immunotherapy, as an emerging tumor treatment option, provides new hope for many cancer patients. However, a large proportion of patients do not benefit from immunotherapy. As a critical cell-to-cell communication mediator in the tumor immune microenvironment, exosomes may play a unique role in hepatocellular carcinoma immune response and thus affect the efficiency of immunotherapy. In this review, we discuss related research on the roles of exosomes in the current immunotherapy resistance mechanism of hepatocellular carcinoma. Furthermore, we also clarify the excellent predictive value of exosomes and the roles they play in improving immunotherapy efficacy for hepatocellular carcinoma patients. We hope that our review can help readers to gain a more comprehensive understanding of exosomes' roles in hepatocellular carcinoma immunotherapy. Hepatocellular carcinoma (HCC) is one of the most lethal malignancies, having a significantly poor prognosis and no sufficiently efficient treatments. Immunotherapy, especially immune checkpoint inhibitors (ICIs), has provided new therapeutic approaches for HCC patients. Nevertheless, most patients with HCC do not benefit from immunotherapy. Exosomes are biologically active lipid bilayer nano-sized vesicles ranging in size from 30 to 150 nm and can be secreted by almost any cell. In the HCC tumor microenvironment (TME), numerous cells are involved in tumor progression, and exosomes—derived from tumor cells and immune cells—exhibit unique composition profiles and act as intercellular communicators by transporting various substances. Showing the dual characteristics of tumor promotion and suppression, exosomes exert multiple functions in shaping tumor immune responses in the crosstalk between tumor cells and surrounding immune cells, mediating immunotherapy resistance by affecting the PD-1/PD-L1 axis or the anti-tumor function of immune cells in the TME. Targeting exosomes or the application of exosomes as therapies is involved in many aspects of HCC immunotherapies (e.g., ICIs, tumor vaccines, and adoptive cell therapy) and may substantially enhance their efficacy. In this review, we discuss the impact of exosomes on the HCC TME and comprehensively summarize the role of exosomes in immunotherapy resistance and therapeutic application. We also discuss the potential of exosomes as biomarkers for predicting the efficacy of immunotherapy to help clinicians in identifying HCC patients who are amenable to immunotherapies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis.
- Author
-
Tian, Bao-Wen, Yan, Lun-Jie, Ding, Zi-Niu, Liu, Hui, Han, Cheng-Long, Meng, Guang-Xiao, Xue, Jun-Shuai, Dong, Zhao-Ru, Yan, Yu-Chuan, Hong, Jian-Guo, Chen, Zhi-Qiang, Wang, Dong-Xu, and Li, Tao
- Subjects
- *
IMMUNE checkpoint inhibitors , *CANCER prognosis , *LIVER , *CIRRHOSIS of the liver , *OVERALL survival , *PROGRESSION-free survival - Abstract
• Hepatocellular carcinoma patients with impaired liver function have poor prognosis after receiving ICIs. • Both ALBI score and Child-Pugh score can stratify HCC patients. • ALBI score is simpler and more reliable for patient stratification than Child-Pugh score. • The incidence of adverse events is not significantly increased in impaired liver function patients. Most patients with hepatocellular carcinoma (HCC) have underlying cirrhosis and a compromised liver function. Immune checkpoint inhibitors (ICIs) have emerged as an important approach for HCC treatment. The purpose of our study was to explore the prognostic significance of liver function in HCC patients receiving ICIs. Hazard ratios (HR) with 95% confidence intervals (CI) were used to evaluate the relationship between liver function and overall survival (OS)/progression-free survival (PFS). 41 articles with 4483 patients with HCC were included. The pooled results revealed that either Child-Pugh score (OS:HR = 2.01,95 %CI:1.69–2.38; PFS:HR = 1.39,95 %CI:1.15–1.68) or albumin-bilirubin (ALBI) score (OS:HR = 2.04,95 %CI:1.55–2.69; PFS:HR = 1.42,95 %CI:1.21–1.67) can predict the patient prognosis. The Child-Pugh score has some degree of subjectivity, and the ALBI score can better stratify patients. Therefore, the ALBI score was used to evaluate patients' liver function and determine treatment options. Further subgroup analysis found that the results of prospective studies were statistically significant only for the ALBI score with regards to OS (HR = 1.69,95 %CI:1.26–2.26). Meanwhile, the effect of liver function on the efficacy of ICIs in the large-sample studies was not as obvious as that in small-sample studies. Moreover, the incidence of adverse events did not significantly increase in patients with impaired liver function. Poor liver function is associated with a poor prognosis in patients with HCC receiving ICIs. The ALBI score is simpler and reliable for patient stratification than the Child-Pugh score. Although the survival time of patients with impaired liver function may be relatively short, ICIs still have great potential for therapeutic applications. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.